Table 10.

Use of IL-2 receptor antibodies in primary immunosuppressive regimens in pediatric liver transplantation

Author	Immunosuppression	No. of patients	Survival (%)		Acute rejection (%)	Follow-up (mo)
			Patient	Graft
Asensio et al[167]	TRL, STER	21	80	80	63	12
	TRL, STER, BAS	34	80	80	30
Strassburg et al[168]	TRL, STER	12			42	28
	CSA, STER, AZA	9			66
	CSA, STER	12			42
	CSA, STER, BAS	21			33
Heffron et al[169]	TRL, MMF, STER	20	85	88	50	24
	TRL,2 MMF, DAC, STER	61	93	73	15
Reding et al[119]	TRL, STER	20			50	12
	TRL, BAS, MMF1	20			25
Ganschow et al[170,171]	CSA, STER	54	94		54	28-52
	CSA, STER, BAS	54	98		17
Schuller et al[172]	TRL, MMF, STER	12			66	14
	TRL, MMF, DAC, STER	18			0	6
Spada et al[120]	TRL, STER	36	91	86	32	24
	TRL, BAS	36	87	80	12

CSA: Cyclosporine; DAC: Daclizumab.

¹Mycophenolate mofetil was given in the first 9 patients.

²Tacrolimus was given starting from postoperative day 7.